Chargement en cours...
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) continues to have the worst 5-year survival of any malignancy. With 338,000 new cases diagnosed and over 300,000 deaths per year globally there is an urgent unmet need to improve the therapeutic options available. Novel immunothera...
Enregistré dans:
| Publié dans: | Ther Adv Med Oncol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6299311/ https://ncbi.nlm.nih.gov/pubmed/30574212 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918816281 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|